Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, closed a $20m Series A financing of Zentera Therapeutics, a biopharmaceutical company with headquarters in Shanghai, China.
DataGrand, a Chinese AI startup that offers Natural Language Processing and RPA service to major enterprises in the nation, closed its CNY 270m (USD 38m) B+ funding round.
Pillar Biosciences, a Natick, Mass.- and Shanghai, China-based NGS clinical cancer diagnostics company, closed a $29.7m Series C financing.
Fourier Intelligence, a Shanghai, China-based robotics startup, completed a Series B+ funding round in excess of tens of milions of yuan.
Points Technology, a Chinese blockchain and AI startup, raised a multi-million US dollar worth Series A financing.
RemeGen, a Yantai, China-based biopharmaceutical company, closed an approximately USD $100m private financing round.
Technology giant Tencent Holdings Limited (00700.HK) launched a US$100 million Global Anti-Pandemic Fund to support international efforts against COVID-19.
Iaso Biotherapeutics, a Nanjing, China-based clinical-stage biotechnology company, closed a $60m series B financing.
Y-Platform, a Chinese multi-channel video network, completed a $3.5m Series A funding round.
Neolix, a Chinese autonomous driving vehicle company, raised nearly RMB 200M in Series A+ funding.
Fenbeitong, a Chinese renowned corporate expense management startup, raised $36M in Series B+ financing.
Harbour BioMed, a Cambridge, MA- Rotterdam, The Netherlands and Suzhou, China-based global, clinical stage biopharmaceutical company, closed its $75m Series B+ round of financing.
Whales English, a Beijing, China-based brand of online K-12 English group classes, completed its RMB100m Series B financing.
CANbridge Pharmaceuticals Inc., a Beijing, China-based biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, completed a US$98m Series D financing.
Mastercard (NYSE: MA) has received in-principle approval from the People’s Bank of China (PBOC) to begin formal preparations to set up a domestic bankcard clearing institution in China.